FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • November 27th, 2012 • Elan Corp PLC • Pharmaceutical preparations
This First Supplemental Indenture, dated as of November 19, 2012 (this “Supplemental Indenture”), among Elan Finance public limited company, a public limited company incorporated and registered under the laws of Ireland (together with its successors and assigns), Elan Finance Corp., a Delaware corporation (together with its successors and assigns, collectively the “Issuers”), Elan Corporation, plc (the “Company”), Neotope Biosciences Limited, a private limited company organized under the laws of Ireland, (“Neotope”), Onclave Therapeutics Limited (“Onclave”), a private limited company organized under the laws of Ireland, and Prothena Biosciences Inc (formerly known as Neotope Biosciences, Inc.), a Delaware corporation (“Prothena” and, together with Neotope and Onclave, the “New Note Guarantors”) and each other Note Guarantor under the Indenture referred to below, and The Bank of New York Mellon, London Branch, as successor trustee (the “Trustee”) under the Indenture referred to below.
